vs
拜玛林制药（BMRN）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Rithm Capital Corp.的1.1倍（$874.6M vs $828.2M），Rithm Capital Corp.净利率更高（13.2% vs -5.3%，领先18.5%），Rithm Capital Corp.同比增速更快（508.5% vs 17.0%），过去两年拜玛林制药的营收复合增速更高（16.1% vs -17.9%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
BMRN vs RITM — 直观对比
营收规模更大
BMRN
是对方的1.1倍
$828.2M
营收增速更快
RITM
高出491.4%
17.0%
净利率更高
RITM
高出18.5%
-5.3%
两年增速更快
BMRN
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $828.2M |
| 净利润 | $-46.6M | $109.5M |
| 毛利率 | 68.5% | — |
| 营业利润率 | -5.1% | 29.9% |
| 净利率 | -5.3% | 13.2% |
| 营收同比 | 17.0% | 508.5% |
| 净利润同比 | -137.3% | 27.7% |
| 每股收益（稀释后） | $-0.22 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $874.6M | $1.5B | ||
| Q3 25 | $776.1M | $1.1B | ||
| Q2 25 | $825.4M | $1.2B | ||
| Q1 25 | $745.1M | $768.4M | ||
| Q4 24 | $747.3M | $2.1B | ||
| Q3 24 | $745.7M | $619.5M | ||
| Q2 24 | $712.0M | $1.2B |
净利润BMRNRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $-46.6M | $85.0M | ||
| Q3 25 | $-30.7M | $221.5M | ||
| Q2 25 | $240.5M | $311.7M | ||
| Q1 25 | $185.7M | $78.8M | ||
| Q4 24 | $124.9M | $290.2M | ||
| Q3 24 | $106.1M | $121.7M | ||
| Q2 24 | $107.2M | $235.6M |
毛利率BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | — | ||
| Q2 25 | 81.8% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | — | ||
| Q2 24 | 81.7% | — |
营业利润率BMRNRITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | -5.1% | 13.8% | ||
| Q3 25 | -6.0% | 21.4% | ||
| Q2 25 | 33.5% | 25.2% | ||
| Q1 25 | 30.0% | 7.4% | ||
| Q4 24 | 21.6% | 23.8% | ||
| Q3 24 | 15.3% | 7.3% | ||
| Q2 24 | 16.9% | 23.6% |
净利率BMRNRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | -5.3% | 5.7% | ||
| Q3 25 | -4.0% | 20.0% | ||
| Q2 25 | 29.1% | 25.6% | ||
| Q1 25 | 24.9% | 10.3% | ||
| Q4 24 | 16.7% | 14.0% | ||
| Q3 24 | 14.2% | 19.7% | ||
| Q2 24 | 15.1% | 19.2% |
每股收益（稀释后）BMRNRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $-0.22 | $0.09 | ||
| Q3 25 | $-0.16 | $0.35 | ||
| Q2 25 | $1.23 | $0.53 | ||
| Q1 25 | $0.95 | $0.07 | ||
| Q4 24 | $0.65 | $0.50 | ||
| Q3 24 | $0.55 | $0.20 | ||
| Q2 24 | $0.55 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $9.1B |
| 总资产 | $7.6B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $1.8B | ||
| Q3 25 | $1.3B | $1.6B | ||
| Q2 25 | $1.2B | $1.6B | ||
| Q1 25 | $1.0B | $1.5B | ||
| Q4 24 | $942.8M | $1.5B | ||
| Q3 24 | $675.4M | $1.6B | ||
| Q2 24 | $972.1M | $1.2B |
总债务BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益BMRNRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $6.1B | $8.4B | ||
| Q3 25 | $6.1B | $8.5B | ||
| Q2 25 | $6.0B | $7.9B | ||
| Q1 25 | $5.8B | $7.8B | ||
| Q4 24 | $5.7B | $7.8B | ||
| Q3 24 | $5.4B | $7.7B | ||
| Q2 24 | $5.3B | $7.3B |
总资产BMRNRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $7.6B | $53.1B | ||
| Q3 25 | $7.6B | $47.2B | ||
| Q2 25 | $7.5B | $44.3B | ||
| Q1 25 | $7.1B | $45.3B | ||
| Q4 24 | $7.0B | $46.0B | ||
| Q3 24 | $6.9B | $42.3B | ||
| Q2 24 | $7.1B | $42.0B |
负债/权益比BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | — |
| 自由现金流经营现金流 - 资本支出 | $58.9M | — |
| 自由现金流率自由现金流/营收 | 6.7% | — |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | — |
8季度趋势，按日历期对齐
经营现金流BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | $99.6M | $-114.6M | ||
| Q3 25 | $368.7M | $-2.0B | ||
| Q2 25 | $185.3M | $-557.1M | ||
| Q1 25 | $174.4M | $1.4B | ||
| Q4 24 | $185.6M | $-1.8B | ||
| Q3 24 | $221.5M | $768.1M | ||
| Q2 24 | $118.8M | $-55.7M |
自由现金流BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — |
自由现金流率BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — |
资本支出强度BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — |
现金转化率BMRNRITM
| Q1 26 | — | — | ||
| Q4 25 | — | -1.35× | ||
| Q3 25 | — | -9.22× | ||
| Q2 25 | 0.77× | -1.79× | ||
| Q1 25 | 0.94× | 18.03× | ||
| Q4 24 | 1.49× | -6.04× | ||
| Q3 24 | 2.09× | 6.31× | ||
| Q2 24 | 1.11× | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
